Showing 2691-2700 of 4063 results for "".
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si
- Moderna Boosts COVID-19 Vaccine Output for 2021 to at Least 600 Million Doseshttps://modernod.com/news/moderna-boosts-covid-19-vaccine-output-for-2021-to-at-least-600-million-doses/2478715/Moderna said it expects to produce a minimum of 600 million doses of its COVID-19 vaccine mRNA-1273 globally this year, up from an earlier estimate of 500 million, and that it is still working to build up to potentially 1 billion doses for 2021. The company also plans to deliver about 100 million
- From COVID-19 to Retail Health: Fierce Healthcare’s Biggest Stories of 2020https://modernod.com/news/from-covid-19-to-retail-health-fierce-healthcares-biggest-stories-of-2020/2478689/The year 2020 was dominated by the fallout from a generational global pandemic. So perhaps it’s no surprise that COVID-19 headlines also governed much of
- Envision Announces Dates, Calls for Submissions for 2021 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2021-conferences/2478668/Envision announced that it is now accepting submissions for clinical education and research presentations for its two 2021 conferences—events with the goal of closing practice gaps and disseminating the latest advancements in rehabilitation techniques, research and technology surrounding low visi
- Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitishttps://modernod.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/Nicox SA announced the initiation of the Mississippi trial, a phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystal
- CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoVhttps://modernod.com/news/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/2478656/CureVac announced that it has enrolled the first participant in the pivotal phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled phase 2b/3 trial
- Hospital Operating Margins Down Nearly 20% Since Start of Year Due to COVID-19, Report Sayshttps://modernod.com/news/hospital-operating-margins-down-nearly-20-since-start-of-year-due-to-covid-19-report-says/2478609/Hospitals and health system operating margins fell nearly 20% since the start of 2020 as COVID-19 continues to roil provider finances, according to a new report from Kaufman Hall, FierceHealthcare
- Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027https://modernod.com/news/report-dry-eye-treatment-devices-market-size-worth-400-8-million-by-2027/2478591/The global dry eye treatment devices market size is estimated to reach US$400.8 million by 2027, expanding at a CAGR of 6.4%, according to a new report by Grand View Research, Inc. The increasing demand for targeted, noninvasive, faster, and patient compliant treatment methods to alleviate dry ey
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi